Ask about this productRelated genes to: LYVE1 antibody
- Gene:
- LYVE1 NIH gene
- Name:
- lymphatic vessel endothelial hyaluronan receptor 1
- Previous symbol:
- XLKD1
- Synonyms:
- LYVE-1
- Chromosome:
- 11p15.4
- Locus Type:
- gene with protein product
- Date approved:
- 2001-03-21
- Date modifiied:
- 2015-07-22
Related products to: LYVE1 antibody
Related articles to: LYVE1 antibody
- - Source: PubMed
Publication date: 2026/08/04
Gao YuxiangLi LanRao XiaohuaZhao LutingXiao Lin - Mitochondria activate immunity, but the role in cancer is unknown. Here, we report that transgenic expression of Parkin, a regulator of mitochondrial fitness, induces inflammation and interferon (IFN) gene signatures, suppresses prostate cancer formation and generates CD8 and CD20 intraprostatic immune aggregates. These had hallmarks of mature tertiary lymphoid structures (TLS), expressing markers of B cell maturation (CXCL13, CCL21), germinal center formation (BCL6, GL7), mature dendritic cells (MHC-II/CD208) and high endothelial venules (LYVE-1). Parkin TLS showed high Ig gene expression, recruitment of CXCR5 follicular T helper cells and expansion of CD69/KLRG1 effector T cells. Conditioned medium from Parkin-positive cells expanded memory B and plasma cells, increased IgG1 production, and sustained B and T cell migration. Finally, conditional expression of Parkin induced TLS formation, upregulated Ig chains and inhibited prostate cancer growth, in vivo, whereas Parkin reconstitution in IFNAR1, CD8 or CD20 knockout mice had no effect. Therefore, mitochondrial immunity orchestrates antitumor responses, and TLS formation contributes to tumor suppression. - Source: PubMed
Publication date: 2026/08/07
Perego MichelaKossenkov Andrew VGhosh Jagadish CCamisaschi ChiaraTursi Nicholas JWeiner David BAltieri Dario C - Secondary lymphedema remains poorly understood, particularly with regard to early human tissue responses after lymphatic outflow disruption. This study evaluates the perforator-based adipocutaneous skin paddle (PBASP) from vascularized free muscle flaps as a hypothesis-generating human tissue platform for early localized lymphatic insufficiency. The PBASP, receives arterial and venous perfusion but is not reconnected to physiological lymphatic outflow and was therefore hypothesized to develop changes consistent with early local lymphatic outflow insufficiency. Tissue samples were collected from 15 patients who underwent free muscle flap transfer, with PBASP samples obtained 7-14 days post-surgery. Histological, immunofluorescence, molecular, and protein analyses were performed to assess lymphangiogenesis, inflammation, extracellular matrix remodeling, and adipogenesis. PBASP tissue exhibited epidermal thickening, dermal expansion, subcutaneous matrix loosening, and leukocyte infiltration. Immunofluorescence showed a 3.6-fold increase in LYVE-1 + lymphatic vessel cross-sectional area. Gene expression analysis revealed upregulation of markers like VEGF-C, VEGFR3, IL-6, and MMP-9. ELISA demonstrated increased LYVE-1, IL-6, and COL1A1 protein levels. Together, PBASP tissues showed structural, lymphatic-marker, inflammatory, and early remodeling changes consistent with early localized lymphatic outflow insufficiency. Together, these findings support the PBASP-derived approach as a paired human tissue platform for studying early, localized lymphatic insufficiency and for generating mechanistic hypotheses relevant to secondary lymphedema. - Source: PubMed
Publication date: 2026/08/05
Koll Katja KZimmermann Martin MSchulte MatthiasPanayi Adriana CHundeshagen GabrielKneser UlrichHirche Christoph - Peritoneal cavity fluid and mesothelial surfaces host distinct resident macrophage populations, among which include the well-described Gata6 large cavity macrophages (LCMs) in peritoneal fluid. Here, we reveal that LCMs arise from two separable differentiation pathways. In the quantitatively minor pathway, monocytes gave rise to LYVE1 LCMs but few Gata6 LCMs. This pathway did not require the transcription factor Gata6 but was severely impaired in mice bearing three mutations in the -165 kb enhancer () with impaired monocyte development. The second, dominant pathway supported Gata6-dependent LCMs and was intact in mice, even when turnover was enforced by irradiation, and was supported by adoptive transfer of a specialized LCM intermediate expressing Gata6 before the residency marker TIMD4. Functionally, the quantitatively minor LCM pathway distinctly surveilled the mesothelium, replenishing mesothelial border macrophages upon encountering an open niche. Thus, beyond embryonic versus adult hematopoietic paradigms, LCMs with overlapping and distinct phenotypes arise from two pathways linked to divergent fates. - Source: PubMed
Publication date: 2026/07/31
Han JichangGallerand AlexandreMintz Rachel LChen JingOu FeiyaGao ShuaiLee Daniel DChan Mandy MHarmon Michael TLin XueRamkhelawon BhamaHuckstep Christopher GStrickland Michael RLiu TiantianLavine Kory JSchilling Joel DMorley S CelesteZinselmeyer Bernd HMurphy Kenneth MRandolph Gwendalyn J - Secondary lymphedema, characterized by localized tissue swelling caused by lymphatic damage or dysfunction, remains a major clinical challenge that compromises quality of life. Current physical therapies provide only temporary relief, underscoring the need for effective regenerative strategies. Here, we report the fabrication of a micropatterned, small-diameter fibrous artificial lymphatic vessel incorporating hyaluronic acid (HA) via electrospinning to enhance lymphatic fluid transport. The engineered scaffold exhibits optimized mechanical properties and elicits favorable cellular responses through HA-mediated biochemical cues. Lymphatic endothelial cells (LEC) cultured on the scaffold show increased expression of lymphangiogenesis-related markers, including Prox1 and LYVE-1, accompanied by AKT activation and increased VEGF-C/VEGFR3-associated marker expression. The topographical features of the scaffold were also associated with altered YAP localization and increased lymphatic endothelial marker expression. In vivo implantation of the scaffold in a rat lymphedema model reduced ankle swelling and lymphatic retention across the surgically disrupted region toward an anatomically preserved drainage basin. Collectively, these findings suggest that HA-integrated fibrous lymphatic scaffolds represent a promising strategy for lymphedema treatment by synergistically engaging biochemical and biomechanical pathways associated with lymphatic repair and functional fluid transport. - Source: PubMed
Publication date: 2026/07/28
Jang Se RimCheon HwayeongChoi So YeunSuh Il WonPark Jung-HoonPark Chan Hee